Hepatocellular carcinoma treatment: hurdles, advances and prospects
Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related mortality and
is particularly refractory to the available chemotherapeutic drugs. Among various etiologies …
is particularly refractory to the available chemotherapeutic drugs. Among various etiologies …
Role of endoglin (CD105) in the progression of hepatocellular carcinoma and anti-angiogenic therapy
A Kasprzak, A Adamek - International Journal of Molecular Sciences, 2018 - mdpi.com
The liver is perfused by both arterial and venous blood, with a resulting abnormal
microenvironment selecting for more-aggressive malignancies. Hepatocellular carcinoma …
microenvironment selecting for more-aggressive malignancies. Hepatocellular carcinoma …
Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors
JC Spina, I Hume, A Pelaez, O Peralta, M Quadrelli… - Radiographics, 2019 - pubs.rsna.org
Transarterial radioembolization (TARE), also called radioembolization or selective internal
radiation therapy, is an interventional radiology technique used to treat primary liver tumors …
radiation therapy, is an interventional radiology technique used to treat primary liver tumors …
Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: Results of the HEPANOVA phase II study
E Gkika, AL Grosu, T Macarulla Mercade… - Cancers, 2022 - mdpi.com
Simple Summary Advanced hepatocellular carcinoma (HCC) is an aggressive liver cancer
with limited treatment options and poor prognosis. Tumor-Treating Fields (TTFields) are …
with limited treatment options and poor prognosis. Tumor-Treating Fields (TTFields) are …
Role of virus-related chronic inflammation and mechanisms of cancer immune-suppression in pathogenesis and progression of hepatocellular carcinoma
M Borgia, M Dal Bo, G Toffoli - Cancers, 2021 - mdpi.com
Simple Summary Hepatocellular carcinoma pathogenesis is dependent on a chronic
inflammation caused by several factors, including hepatotropic viruses, such as HCV and …
inflammation caused by several factors, including hepatotropic viruses, such as HCV and …
Highly tumor-specific and long-acting iodine-131 microbeads for enhanced treatment of hepatocellular carcinoma with low-dose radio-chemoembolization
Y Qian, Q Liu, P Li, Y Han, J Zhang, J Xu, J Sun, A Wu… - ACS …, 2021 - ACS Publications
Transarterial radioembolization (TARE) is considered the standard treatment for
intermediate-stage hepatocellular carcinoma (HCC). Iodine-131 (131I)-labeled lipiodol …
intermediate-stage hepatocellular carcinoma (HCC). Iodine-131 (131I)-labeled lipiodol …
Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor
Abstract Doxorubicin (DOX)-loaded, hyaluronic acid-ceramide (HACE) nanoassembly-
releasing poly (lactic-co-glycolic acid)(PLGA) microspheres (MSs) were developed for …
releasing poly (lactic-co-glycolic acid)(PLGA) microspheres (MSs) were developed for …
Microspheres as a carrier system for therapeutic embolization procedures: Achievements and advances
MM Welling, N Duszenko, MP van Meerbeek… - Journal of Clinical …, 2023 - mdpi.com
The targeted delivery of anti-cancer drugs and isotopes is one of the most pursued goals in
anti-cancer therapy. One of the prime examples of such an application is the intra-arterial …
anti-cancer therapy. One of the prime examples of such an application is the intra-arterial …
[HTML][HTML] Radioembolization for hepatocellular carcinoma: what clinicians need to know
Transarterial radioembolization (TARE) with yttrium 90 (90 Y) has been used in the
management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are …
management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are …
[HTML][HTML] The modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma …
Methods In total, 102 patients with unresectable intrahepatic HCC, who were treated with
TARE between 2012 and 2017, were reviewed retrospectively. The treatment response after …
TARE between 2012 and 2017, were reviewed retrospectively. The treatment response after …